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Abstract
Background The economic burden linked to rheumatoid
arthritis (RA) has greatly increased since the inclusion of
biotherapies in the therapeutic arsenal.
Objectives This study aimed first to look at the breakdown of
the rheumatoid arthritis patients on biotherapy in Alsace,
France, in 2012, then to evaluate the annual cost per treated
patient for each management pathway: inpatient care with
intravenous biotherapies and/or outpatient care through the use
of subcutaneous drugs, andfinally to conduct a cost comparison
with a focus on infliximab, adalimumab and etanercept.
Methods This observational study was conducted in Alsace
using 2012 health claims data from the DCIR (Donne´es de
Consommation Inter Re´gime) and PMSI (Programme de
Me´dicalisation des Syste`mes d’Information) databases, taking
into account direct medical and non-medical costs in a real-life
setting and from a National Health Insurance perspective.
Results There were 5702 RA patients, i.e. 0.31 % of the
Alsace population in 2012, including 1075 subjects
(18.85 %) receiving biotherapy treatment. The most fre-
quently prescribed biotherapies were etanercept and adal-
imumab. The estimated overall cost of care of these 5702
patients was €30.3 million, with about 50 % for the care of
the 18.85 % patients on biotherapy. Average costs for
inpatient, outpatient and mixed care ranged from €14,197
to €16,873 per patient per year. Annual average cost for
management of a single RA patient with infliximab was
significantly higher than with adalimumab and etanercept:
€16,480 versus €14,116 and €14,338, respectively.
Conclusion These findings confirm the trends of initial
modelling approaches and quantify the cost difference
between various biotherapy management pathways.
Key Points
The study included rheumatoid arthritis (RA)
patients treated with any of the nine biotherapies
available in 2012 in France, and evaluated the annual
cost per patient through a data linkage between
inpatient and outpatient care for the same individual.
Outpatient care was the main management pathway
observed. Etanercept and adalimumab were the most
commonly used biotherapies to treat RA patients.
Biotherapy acquisition costs and hospital stays were
the two main areas of expenditure.
Annual average cost per RA patient management
with infliximab was significantly higher compared to
patients treated with adalimumab or etanercept. The
highest cost of infliximab was essentially explained
by the additional hospitalization cost associated with
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1 Introduction
The last decade saw the transition for the treatment of
moderate-to-severe rheumatoid arthritis (RA) from gen-
eral immunomodulators to biotherapies. Recent thera-
peutic guidelines have positioned the biotherapies in the
therapeutic arsenal [1–5]. Early treatment of RA with
biotherapies translates into substantial cost savings as
they appear to improve work ability or prevent future
orthopaedic surgery. However, these biological drugs are
associated with high procurement costs [6–8].
In parallel, sweeping changes in the organisation of the
French healthcare policy have occurred with the imple-
mentation since 2004 of a Diagnosis-Related-Groups
(DRG) based payment system correlating the government
funding of each hospital with specific activity parameters.
In addition to the above, innovative and expensive drugs
like biotherapies are included in a restricted list: they are
completely funded in addition to hospitalisation stays. This
payment scheme enables all hospitals to have access to
these therapies. However, the percentage of range of cost
increase for these innovative drugs is pre-defined at a
national level, in an attempt to control the cost expenditure
[9].
In this context of close health cost control, a better
understanding of how biotherapies impact the costs of
managing RA will allow improvement in decisions
concerning resource allocation, and also reinforce the
compliance with therapeutic guidelines. Predicting the
annual cost of biotherapies is complex due the differ-
ences in dosing schedules. Furthermore, patients may not
respond and may require dose escalation over time or a
switch between biotherapies. Some biotherapies are only
administered at the hospital while others can also be
administered by subcutaneous (SC) route at home,
leading to different management pathways [10]. SC
biotherapies affect outpatient care expenditure, while
intravenous (IV) biotherapies have an impact on hospital
expenses. Those differences can lead to a potential
reduction of hospital activity which in turn needs to be
anticipated.
This study aimed first to look at the breakdown of the
RA patients on biotherapy in 2012 in Alsace, and second
to estimate the annual cost per treated patient for each
management pathway: inpatient care with IV medications
and/or outpatient care through the use of SC drugs, all in
a real-life setting, and finally to complete a cost com-
parison with a focus on infliximab, adalimumab and
etanercept.
2 Patients and Methods
2.1 Data Source
A retrospective observational study was conducted by
OMEDIT Alsace (Observatoire du Me´dicament, des Dis-
positifs me´dicaux et de l’Innovation The´rapeutique) using
administrative claims data from the DCIR (Donne´es de
Consommation Inter Re´gime) and PMSI (Programme de
Me´dicalisation des Syste`mes d’Information) databases
from 1 January 2012 to 31 December 2012. Alsace is a
French administrative region that accounted for 1.86 mil-
lion inhabitants in 2012 at whatever age, i.e. 3 % of the
French population, and among them 1.41 million people
aged 20 years or over.
Data relative to outpatient care and to inpatient care are
stored and linked into the DCIR datamart that is part of the
SNIIRAM (Syste`me National d’Information Interre´gimes
de l’Assurance Maladie) data warehouse of National
Health Insurance, that records anonymised data about
patients who benefit from medical care with intent of
having adequate knowledge on expenses concerning all
health insurance schemes, thus enabling evaluation of
public health policy. The main benefit of its use for epi-
demiological purposes is to have access to information
about the healthcare circuit including hospitalisation and
outpatient care for the same individual. Its access is
restricted to authorised people specified through a national
policy. Information strictly required for the purpose of the
study was provided in the form of anonymised and
aggregated data by DRSM (Direction Re´gionale du Service
Me´dical) Alsace-Moselle that has access to DCIR and
PMSI databases with respect to the approval of the French
data protection authority CNIL (Commission nationale de
l’informatique et des liberte´s). Data extracted concerned
the patient population residing and insured in Alsace under
the general scheme managed by CNAMTS (Caisse Natio-
nale de l’Assurance Maladie des Travailleurs Salarie´s),
which covered 80 % of residents in Alsace in 2011 [11].
2.2 Rheumatoid Arthritis Patient Population
RA is one of the chronic diseases included in the Long
Term Diseases (LTD) list for which CNAMTS provides
100 % health insurance coverage. Data extracted from the
DCIR and PMSI databases enabled us to consider all RA
patients in a real-life setting. The RA patients included in
the study were defined as patients residing and insured in
Alsace under the general scheme managed by CNAMTS,
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who were at least 20 years or older and who had RA
classified as LTD no. 22, irrespective of whether or not
they had another disease classified as another LTD with the
exception of LTD no. 24 (ulcerative colitis and Crohn’s
disease) and LTD no. 27 (severe active ankylosing
spondylitis), since some biotherapies are also approved for
use in patients with one or both of these latter diseases [10].
Data pertaining to hospitalisation were described with the
possible attribution of one of the following diagnostic
codes as the principal or related diagnosis as per the ICD-
10 (International Classification of Diseases—10th revi-
sion), namely code M05: seropositive rheumatoid arthritis
and code M06: other rheumatoid arthritis. The main point
for defining a RA population was of having LTD no. 22
with or without hospitalisation with RA codes encoded as
primary or secondary diagnosis.
2.3 Biotherapies
Several biotherapies were indicated for the treatment of RA
in France in 2012 (see Table 1): infliximab, abatacept,
tocilizumab and rituximab, which were administered by
infusion at hospital, and adalimumab, etanercept, goli-
mumab, certolizumab and anakinra, which were adminis-
tered by SC route at home [10]. RA patients were included
in the biotherapy group as they had at least one claim for a
biotherapy treatment registered in the DCIR in 2012. Three
biotherapy management pathways have been distinguished:
inpatient care that corresponds to patients who are sys-
tematically administered biotherapy treatment by infusion
at hospital, whether or not they switch from an IV bio-
therapy to another IV biotherapy during the year of the
study; outpatient care that groups patients who are sys-
tematically administered biotherapy treatment by the SC
route at home, whether or not they switch from a SC bio-
therapy to another SC biotherapy during the study period;
and finally mixed care that clusters patients who switch
from IV biotherapy to SC biotherapy or vice versa.
2.4 Costs
The viewpoint of the study was that of the French National
Health Insurance CNAMTS.
The following direct medical and non-medical cost
categories were taken into account for each patient, whe-
ther or not he was on biotherapy, and rounded up to the
nearest 10 euros: costs for treatment include cost of bio-
therapy and concomitant medications, and management
costs including inpatient and outpatient care. Inpatient care
costs were determined on the basis of the 2012 French
tariffs per DRG relative to hospitalization in medical,
surgical and obstetric wards. Cost data regarding outpatient
care were relative to consultation with a general
practitioner or a specialist, cost of SC injections adminis-
tered at home by nurses were included as well. Other costs
included expenses incurred for performing laboratory tests,
radiology examinations and kinesitherapy on the patient. A
last cost category related to transport expenses. Since all
patients included in the study had a RA classified as LTD
no. 22, all costs were fully covered by the French National
Health Insurance CNAMTS, so that the total expenditure
was taken into account.
2.5 Statistical Analysis
Afirst descriptive analysis was carried out in order to describe
the biotherapy distribution in the entire RA population, and to
calculate the overall cost to support theRApatient care. Then,
patients considered to be treated for less than 8 months with
biotherapies in 2012 were dropped from the study in order to
get a more realistic value of the actual annual average cost per
RA patient management. Otherwise, this would have led to an
under-estimation of its value. Comparison of demographic
variables and clinical characteristicswere performedusing the
Chi-square test, since all of the variables were categorical
variables. Annual average costs per patient stratified by bio-
therapy and concerning infliximab, adalimumab and etaner-
cept were compared using the Mann–Whitney U test. A
sensitivity analysiswas carried out in order to check if costs of
managing RA with biotherapies were robust to changes in
biotherapy treatment duration, if patients were treated for
more than 6, 8 or 10 months.
A p value below 0.05 was considered to be of statistical
significance. Computations were performed using R, ver-
sion 3.1.0.
3 Results
3.1 Biotherapy Distribution in the Patient
Population
There were 5702 RA patients, i.e. 0.31 % of overall pop-
ulation of Alsace in 2012, of whom 1075 (18.85 % of RA
patients) were under biotherapy treatment. Outpatient care
represented 63.8 % of situations studied whereas inpatient
care and mixed care reached 32.5 and 3.7%, respectively,
of the overall health care for RA. Each of the three sub-
groups was divided into different treatment groups,
according to the modalities that are described in Table 2.
Infliximab, adalimumab and etanercept treatment without
any switch during the year represented about two-thirds
(66.1 %) of the different management pathways observed.
The most commonly used biotherapies were etanercept and
adalimumab, which were used for 368 patients (31.4 %)
and 339 patients (28.9 %), respectively, whether or not
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they switched to another biotherapy. This was followed by
IV biotherapies: abatacept which was used to treat 59
patients (5.0 %), tocilizumab and rituximab were used to
treat a total of 201 patients (17.2 %), and infliximab was
used to treat 137 patients (11.7 %). Overall, 844 patients
(72.0 %) were prescribed infliximab and/or adalimumab
and/or etanercept. Other SC biotherapies listed here were
among the least represented with only 69 patients thus
treated (5.9 %) in 2012: 51 with certolizumab, ten with
anakinra and eight with golimumab. The main mixed care
switch was between adalimumab and IV biotherapy (11
patients, i.e. 27.5 %). The second situation experienced
was a switch between etanercept and IV biotherapy (nine
patients, i.e. 22.5 %). Over the total mixed care switch
situations encountered, 35 situations (87.5 %) involved at
least one anti-TNF treatment.
3.2 Description of Cost Categories
Overall cost to support the 5702 RA patient care in Alsace
in 2012 was €30.3 million, and costs related to the 18.85 %
of RA patients on biotherapy accounted for €14.9 million,
representing 49.2 % of this total amount. Biotherapy
acquisition cost represented the largest part of the cost
attributable to RA treatment containing biotherapies, fol-
lowed by hospitalisation cost. In fact, about €10 million
could be attributed to the procurement of the biological
drugs and €2.4 million linked to hospital facilities, i.e. 67.5
and 16.2 % of the overall expenditure regarding RA
patients treated with biotherapies. Almost a quarter of total
cost allocated to the management of RA patients that were
not treated with biotherapies was attributed to visits to
physicians. Details are provided in Table 3.
3.3 Baseline Clinical and Demographic
Characteristics
After excluding the 213 patients treated for less than
8 months with biotherapies in 2012, a total of 862 patients
under biotherapy remained for the analysis. A patient
selection flowchart is provided in Fig. 1. In the remaining
RA population (n = 5489), the male/female sex ratio was
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0.38 (n = 1516 vs. 3973) and the median age range was
60–69 years. Patients on biotherapy were younger, had
fewer comorbidities recognised as LTD and consulted a
general practitioner or a specialist more frequently. Base-
line characteristics of the study population are summarised
in Table 4.
3.4 Comparison of Annual Average Costs
per Patient
Annual average costs relative to inpatient, outpatient and
mixed care are given in Table 5. When looking at patients
treated for at least 8 months with biotherapy, biotherapy
acquisition costs and hospital stays were the two major
items of expenditure, representing 83.4 % of the total
expenses of inpatient care, and 84.4 % of total expenses of
mixed care. The amount allocated to biotherapy acquisition
reached in itself 80.7 % of the total outpatient care
expenses.
Table 6 shows annual average costs per patient with a
focus on the three anti-tumour necrosis factor alpha (anti-
TNF a) therapies infliximab, adalimumab and etanercept,
without any switch during the study period. There were no
significant cost differences between adalimumab and
etanercept, with the exception of biotherapy acquisition,
which was greater for adalimumab, and for nurse visits and
laboratory tests, which were greater for etanercept. When
comparing infliximab with adalimumab and with etaner-
cept, there were no cost differences relative to visits to
physicians, nurse visits, kinesitherapy and radiology. Costs
relative to biotherapy acquisition were higher for adali-
mumab and etanercept, and those relative to transport,
Table 2 Biotherapy management pathways of adult rheumatoid arthritis patients in Alsace in 2012
Biotherapy management pathways Number of patients %
Inpatient care 349 32.5
Infliximab without any switch 117 10.9
IV biotherapy (other than infliximab) with or without any switch 224 20.8
Switch infliximab and IV biotherapy (other than infliximab) 8 0.7
Outpatient care 686 63.8
Adalimumab without any switch 284 26.4
Etanercept without any switch 310 28.8
Switch adalimumab and etanercept 31 2.9
Switch adalimumab and SC biotherapy (other than adalimumab and etanercept) 7 0.7
Switch etanercept and SC biotherapy (other than adalimumab and etanercept) 8 0.7
SC biotherapy (other than adalimumab and etanercept) with or without any switch 46 4.3
Mixed care 40 3.7
Switch SC biotherapy and IV biotherapy 40 3.7
Total 1075 100.0
SC subcutaneous, SC biotherapy golimumab, certolizumab, anakinra, IV intravenous, IV biotherapy abatacept, tocilizumab, rituximab
Table 3 Breakdown of costs to support the care of rheumatoid arthritis patients in Alsace in 2012











Biotherapy 10,068,780 0 3,131,030 6,498,810 438,940
Visits to physicians 4,807,180 3,828,230 318,080 621,670 39,200
Nurse visits 1,425,350 1,259,780 66,930 89,310 9330
Kinesitherapy 1,160,790 951,370 79,010 123,770 6640
Transportation 1,127,200 769,920 213,170 127,990 16,120
Laboratory tests 1,760,340 1,293,160 203,220 241,420 22,540
Radiology 1,167,390 910,010 87,480 159,770 10,130
Hospital facilities 8,799,530 6,389,000 1,480,000 809,180 121,350
Total cost 30,316,560 15,401,470 5,578,920 8,671,920 664,250
Analysis and Breakdown of Costs Among Rheumatoid Arthritis Patients Treated with Biotherapies 209
Fig. 1 Patient selection flowchart of adult rheumatoid arthritis patients in Alsace in 2012. SC subcutaneous, SC biotherapy golimumab,
certolizumab, anakinra, IV intravenous, IV biotherapy abatacept, tocilizumab, rituximab



















20–29 104 (1.9) 76 (1.6) 40 (3.7) 12 (5.6) 28 (3.2)
30–39 274 (5.0) 203 (4.4) 96 (8.9) 25 (11.7) 71 (8.2)
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50–59 1075 (19.6) 796 (17.2) 325 (30.2) 46 (21.6) 279 (32.4)
60–69 1243 (22.6) 1037 (22.4) 255 (23.7) 49 (23.0) 206 (23.9)
70–79 1132 (20.6) 1033 (22.3) 125 (11.6) 26 (12.2) 99 (11.5)
C80 1059 (19.3) 1034 (22.3) 30 (2.8) 5 (2.3) 25 (2.9)
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laboratory tests and hospitalisation were greater for
infliximab. Annual average cost per RA patient manage-
ment with infliximab was significantly higher than those
with adalimumab and etanercept: €16,480 vs. €14,116 and
€14,338, respectively. The higher cost of infliximab was
mainly explained by additional hospitalisation costs linked
to hospital facilities, transportation and more frequent
laboratory tests. A sensitivity analysis was carried out and
showed the costs of managing RA with biotherapies were
robust to changes in biotherapy treatment duration, so that
the average cost per RA patient management with inflix-
imab was lower than that with adalimumab and etanercept,
whether they were treated for more than 6, 8 or 10 months.
4 Discussion
Previous pharmacoeconomic assessments compared costs
for administering biotherapies for treating inflammatory
rheumatic diseases at both the national and international
levels [12–19]. French analyses were theoretical approa-
ches and/or took into consideration only the data extracted
from hospital databases (PMSI) [12, 13]. This appears to be
the first French study describing inpatient and outpatient
costs of biotherapy management pathways in RA using
data collected from the National Health Insurance claims
database. The study indicates that 18.85 % of RA patients
were treated with biotherapies in Alsace in 2012, which
represented €14.9 million of the total expenses, and this
accounts for almost half of the total amount allocated to
treat all RA patients.
There were 5702 patients with RA classified as a LTD no.
22, corresponding to 0.31 % of the inhabitants in Alsace in
2012 when using the number of people whatever their age,
i.e. 1.86 million inhabitants. We chose to calculate the
percentage of RA patients using the number of people
whatever their age, since the number of RA patients under
20 years old was considered to be negligible, as it repre-
sented 1.5 % of entire population with RA classified as LTD
no. 22. When only considering the number of 1.41 million of
people aged 20 years or over in Alsace in 2012, the pro-
portion of RA patients for this age group increased to
0.40 %. Although this result cannot be treated as prevalence
per se, it is consistent with data from the French EPIRHUM-
2 (Epide´miologie des rhumatismes inflammatoires) survey
that showed in 2001 a RA prevalence of 0.31 % in France,
as well as in Lorraine, which is a border region of Alsace
[20, 21]. Another study conducted in the northern part of
France indicated a prevalence of RA of about 0.20 % in
2005 [22]. Demographic results are coherent with previous
studies such as the EPIRHUM-2 survey that showed there
was a higher age-specific prevalence of RA in the
65–74 years age range, and a 2004 study that described the
characteristics of RA patients managed by hospital-based
rheumatologists in France and showed a male/female sex
ratio of 0.29 and a mean age of 56.7 years [23].
When ranking the number of patients under biothera-
pies, the main management pathway encountered was that
of outpatient care (63.8 %), and more than 60 % of patients
were treated with etanercept or adalimumab. This result
supports previous findings of national and international
studies showing that outpatient care is an option used
extensively in everyday practice [12–17]. The lower use of
golimumab, certolizumab and abatacept in 2012 can be
explained by the fact that they were commercialised later
(September 2012, April 2010 and December 2011,
respectively). Few changes in the administration route of
the biotherapy treatment were observed during the year in
our study: less than 4.0 % of mixed care that could cor-
respond to intolerance or to non-responders, due to the
emergence of resistance or to a poor adherence to
treatment.
Table 6 Average cost (mean ± standard deviation, in euros) of adult rheumatoid arthritis patients treated for at least 8 months with infliximab
(INF), adalimumab (ADA) or etanercept (ETA), without any switch, in Alsace in 2012
Cost domain INF (n = 109) ADA (n = 217) ETA (n = 221) p value INF/ADAa p value INF/ETA p value ADA/ETA
Biotherapy 10,345 ± 5125 11,630 ± 2356 11,437 ± 2669 \0.01* \0.01* 0.01*
Visits to physicians 898 ± 691 832 ± 571 893 ± 619 0.23 0.54 0.40
Nurse visits 87 ± 305 138 ± 577 161 ± 641 0.45 0.20 0.04*
Kinesitherapy 151 ± 355 189 ± 436 213 ± 466 0.91 0.63 0.64
Transportation 493 ± 862 111 ± 421 133 ± 437 \0.01* \0.01* 0.59
Laboratory tests 499 ± 316 311 ± 206 351 ± 227 \0.01* \0.01* 0.03*
Radiology 219 ± 183 209 ± 211 212 ± 206 0.87 0.61 0.44
Hospital facilities 3788 ± 3270 696 ± 2124 938 ± 2658 \0.01* \0.01* 0.29
Total cost 16,480 ± 6677 14,116 ± 3736 14,338 ± 4187 \0.01* \0.01* 0.56
* Statistically significant, Mann–Whitney U test
a Comparison between INF and ADA after matching based on age groups (n = 109)
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The study showed that the average cost of adult RA
patients treated with IV biotherapies seemed to be higher
than that of outpatient care, and that the average cost for
patients treated with infliximab was significantly higher
than that with adalimumab and etanercept. This finding was
quite surprising since the biological follow-up is supposed
to be the same whatever the type of biologic used. We
assumed that patients under treatment with infliximab may
have a systematic biological follow-up when they go to
hospital, and are followed more closely than patients under
SC biotherapies. Moreover, recommendations for moni-
toring RA patients treated with anti-TNF a are: one bio-
logical follow-up (liver function tests and complete blood
count) at 1 and 3 months, then every 3 months for SC
biotherapies, and a biological follow-up at each perfusion,
such as every month for infliximab. The monitoring fre-
quency difference could account for why laboratory tests
are more costly in the infliximab group.
Cost comparison is only valuable when efficacy and
safety of drugs are comparable. Previous studies demon-
strated that biotherapies were effective treatments com-
pared to placebo or conventional drugs, and a 2010 meta-
analysis showed there were no significant differences in
efficacy at 24 weeks between etanercept, adalimumab and
infliximab with or without methotrexate treatment [24, 25].
A 2014 review indicated there was no difference in efficacy
or in the side-effect profiles between IV and SC biothera-
pies [26]. Moreover, marketing authorisation for use in RA
was granted for a sufficient period of time so that inflix-
imab, adalimumab and etanercept benefited from a partic-
ularly extensive post-marketing experience, making the
comparison between those three anti-TNF a therapies
available [10]. Cost comparison demonstrated RA patient
management was less costly with adalimumab or etaner-
cept than with infliximab. The main cost difference
between the three biotherapy options was the hospitalisa-
tion cost, which was significantly greater for the IV med-
ication than for SC drugs. When comparing these results
with those of international studies evaluating costs in the
setting of real world data, it is now obvious that treatment
with infliximab is the most expensive. In fact, Schabert
et al. [14] carried out a study looking at the annual cost per
patient from the payer perspective for etanercept, adali-
mumab and infliximab in adults with rheumatoid arthritis,
psoriasis, psoriatic arthritis or ankylosing spondylitis [14].
They showed that the annual cost per treated RA patient
was lowest for etanercept, followed by adalimumab and
infliximab (US$16,787 vs. US$19,308 and US$22,939,
respectively). The main difference from our study is the
identification of a cost difference between adalimumab and
etanercept. However, this study did not conduct a direct
comparison of these costs and took only the costs of
acquisition and administration of biotherapies into account.
A retrospective USA claims analysis providing an evalu-
ation of drug utilisation and costs in a population of RA
patients treated with one of the three anti-TNF a treatments
conducted by Bonafede et al. [16] led to the same con-
clusions than the study of Schabert et al. [14], with an
annual cost per treated patient of US$18,466 for etanercept,
US$20,983 with adalimumab and US$26,516 with inflix-
imab. Here again, the main differences compared to our
study are the following: a direct statistical comparison of
costs was not planned nor conducted, and the study only
considered direct costs as acquisition and administration of
biotherapies. In another survey, Zeidler et al. [19] studied
real-life data on costs and dosing patterns in the utilisation
of adalimumab, etanercept and infliximab in patients trea-
ted in Switzerland for inflammatory rheumatic diseases.
Their conclusions were the same as ours when considering
daily costs of treatment. They showed that medication costs
were by far the most important cost driver, and that daily
costs of treatment were similar for etanercept and adali-
mumab, but were higher for infliximab. One of the main
assets of this study was a more complete analysis of direct
costs, including, for example, laboratory tests. This anal-
ysis, however, was conducted on the entire population
suffering from inflammatory rheumatic diseases without
any differentiation between RA, ankylosing spondylitis and
psoriatic arthritis.
The current study describes direct medical and non-medi-
cal costs taking all biotherapies into account and in a real-life
setting. Aside from the possible criticism that quality of
medico-administrative databases is more debatable than that
of registries devoted to epidemiological surveillance, it is
important to recognise that their quality improvement in terms
of content and encoding is a constant concern for both
CNAMTS and supervisory authorities [27]. The primary goal
of medico-administrative databases is to provide information
about management and payment of medical care, but their
usefulness to support epidemiological studies is now well
recognised thanks to their frequent updating and compre-
hensiveness that allows their use for recent years at more fine-
tuned geographical levels. These tools are an asset for studies
related to healthcare issues and to the optimisation of the
resources management. Moreover, due to their compulsory
fulfilling, few data are missing from those databases in con-
trast to some studies that require data collection in a declara-
torymode [28]. It is also important to note that the price of the
medicines remained stable over the entire year of the study.
The study had some limitations. Firstly, patients who
were not insured under the general scheme were not taken
into account. Secondly, data about indirect and intangible
costs are lacking because of their relative complexity.
Therefore, cost of illness is underestimated but cost com-
parison should not have been affected since indirect and
intangible costs are considered to be the same in each
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group. Thirdly, it may be noted that the study provided a
snapshot of biotherapies used at a given point in time and
did not allow for the observation of changes in prescribing
practices over a longer period. Finally, existence of con-
founding by indication cannot be ruled out. That bias lar-
gely met in observational studies would reflect the fact that
IV biotherapies could be prescribed in preference to
patients who are more fragile than those under SC bio-
therapies. The differences in patient’s characteristics could
lead to a greater cost in the infliximab subgroup, but that
bias is likely to be limited in this study because all bio-
therapies are indicated to treat RA at the same stage [10].
The choice of the practitioner to treat with either IV or SC
biotherapies is more based on patient’s comprehension of
his condition and possible adherence to treatment than on a
potential frailty. Moreover, a further qualitative analysis of
consumption of the medication was carried out and con-
firmed there was no difference in term of concomitant
medication in patients treated with infliximab, adalimumab
or etanercept.
5 Conclusion
The results showed that costs of RA management lies not
only in the price of biotherapies, but also in the cost of
hospitalisation of inpatient care. Treatment with infliximab
was more costly than with adalimumab or etanercept.
These findings are aligned with the beliefs of both national
and international publications that demonstrate inpatient
care is more expensive than outpatient care, primarily
because of hospitalisation costs [12, 14–17]. If all RA
patients treated with infliximab in Alsace throughout 2012
had switched to adalimumab or etanercept, the total cost
savings would have reached €250,000 at a regional level.
Extrapolating to the whole country population, the annual
cost saving could be more than €8.3 million. However,
even if the study provides strong evidence that infliximab is
more expensive than adalimumab or etanercept, final
conclusions have to be made in the light of additional
concepts such as the notion of quality of life, and some
further studies are needed to prove outpatient care is indeed
the most cost-effective way to treat RA patients.
Recent market approval of biosimilar medicines will
lead to a repositioning of the different RA biotherapy
management pathways. For instance, biosimilar infliximab
has obtained its European marketing authorisation for RA
in September 2013, and its cost should be about 30 %
lower than the non biosimilar compound [29]. Likewise,
tofacitinib, an oral treatment approved in more than 20
countries, could significantly affect RA patients’ manage-
ment. The medico-administrative databases should provide
an effective support to better evaluate the changes brought
by the latest innovations and to shed a new light on
questions related to the reduction of healthcare expenses.
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